Thank you Yale School of Medicine Rheumatology 2023 International State-of-the-Art Symposium for the opportunity to discuss Real World Evidence #RWE applied to #rheumatology. Clinical medicine has a new vocabulary to master! e.g. negative control outcomes, E-values and more!

Thrilled to be celebrating the evening with some of my family and 65,000+ Swifties tonight in Atlanta!

Fun to hang out and talk with @NamrataRheum about detangling malignancy risk, Biologics/Jaki and #RA as a UAB Clinical Immunology and Rheumatology visiting professor!

Moderna files with FDA for updated monovalent COVID fall booster targeting XBB 1.5, a newer, common Omicron subvariant. The anticipation that recommended COVID-19 boosting morphs into a seasonal event like the flu shot is becoming a reality.

#rheumatology providers & pts may be increasingly indifferent towards #Covid19 boosting, but risk for infection is not the same as risk for severe dz. At-risk patients may be at same or lower risk for transmission yet 3-15x higher risk for hospitalization. cdc.gov/coronavirus/20…

A recent trial of non-invasive, auricular vagus nerve stimulation (VNS) to treat #RheumatoidArthritis failed, but that shouldn't diminish enthusiasm for implantable VNS that may benefit RA, #IBD, or other autoimmune diseases, currently in Phase 3 trials. onlinelibrary.wiley.com/doi/epdf/10.10…

That’s a wrap! This year’s excellent #epidemiology ISPE conference in Halifax focused on real-world evidence #RWE. Health equity and #AI - enabled patient generated digital health data embedded in Software as a Medical Device (SaMD) featured prominently. #ICPE2023

Find it challenging to communicate risks and benefits of medications to your #rheumatology pts? Following a recent Dr. John Cush discussion (9/5/23), this new A&R article provides practical guidance using examples from the tofacitinib Oral Surveillance trial. pubmed.ncbi.nlm.nih.gov/37909387/

Dr Ted Mikuls gives a great overview of 20 years of success in the VA RA registry at #ACR2023 deriving insights about #rheumatoid arthritis Rx effectiveness, ILD and more. Wishing him congrats and a happy birthday today.

Enjoying Casablanca tonight with my sweetheart at the iconic #alabamatheater #ValentinesDay

Very appreciative to STAR Texas #rheumatology for their kind invitation to discuss new #covid19 and #shingles #vaccine data and how to overcome vaccine hesitancy! Thankful to be included in such an august cadre of speakers this weekend.

Great talk by Dr Skip Rizzo alongside many others at #vMed24 describing how to increase the rigor of designing trials of medical extended reality (MXR) interventions in diverse healthcare settings to improve patient outcomes and increase wellness.

RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses. Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/Jeffrey Curtis Dr. John Cush

Privileged to be at #CSRO discussing how generative and predictive #AI can support #rheumatology in value based care and reimbursement and its potential pitfalls. Fantastic group of people advocating for our field and especially our patients. #VBR #VBC CSRO

Great talk at #RNL2025 by Dr Una Makris on managing geriatric rheumatology patients. How often do we under-treat #Rheumatoid arthritis patients with advanced therapies because we fall into the trap of ageism?

NEW! Can #AI improve how we diagnose, treat, & monitor #rheum patients? In our latest episode, we explore AI’s growing role in #rheum & where it’s taking us next with Jeffrey Curtis. Listen HERE → acr.tw/4cErWTU

This week in A&R TMP-SMX significantly reduces risk of serious infections in AAV patients receiving RTX or CYC induction therapy doi.org/10.1002/art.43… No evidence of increased CV events during 1st 2 years of JAKi use vs TNFi in RA patients doi.org/10.1002/art.43…

US- Top Drug Rx Sales in 2024 Semaglutide $54 Billion Tirzepatide $31.7 B Adalimumab $28B Apixaban $26 B Empagliflozin $20.5 B Pembrolizumab $18 B Ustekinumab $17 B Risankizumab $16 B Dupilumab $15.6 B Etanercept $10.1 B Secukinumab $7.7 B Immune globulin $7.1 B Upadacitinib $7

The FDA just completed its first AI-assisted scientific review—marking a historic shift in how new therapies are evaluated. Tasks that took days now take minutes. An AI revolution is underway inside the agency. If this is the start, what’s next? ⚖️🤖💊 fda.gov/news-events/pr…

#AI isn’t coming for your job—it’s coming to join your care team. Excited to explore today how AI is reshaping the future of medicine with California’s top #rheumatology providers at CalRheumAlliance. #AI #MedTech #RheumCare